Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The GMZ2 malaria vaccine: from concept to efficacy in humans

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A vaccine targeted specifically to prevent cerebral malaria - is there hope?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pre-clinical and clinical development of the first placental malaria vaccine

    Research output: Contribution to journalReviewResearchpeer-review

  3. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

    Research output: Contribution to journalReviewResearchpeer-review

  4. The case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malaria

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: GMZ2 is a recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens of Plasmodium falciparum, and is designed with the aim of mimicking naturally acquired anti-malarial immunity. The rationale for combining these two antigens is based on a series of immune epidemiological studies from geographically diverse malaria endemic regions; functional in vitro studies; and pre-clinical studies in rodents and New World monkeys. GMZ2 adjuvanted with alhydrogel® (alum) was well tolerated and immunogenic in three phase 1 studies. The recently concluded phase 2 trial of GMZ2/alum, involving 1849 participants 12 to 60 month of age in four countries in West, Central and Eastern Africa, showed that GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population. Areas covered: PubMed ( www.ncbi.nlm.nih.gov/pubmed ) was searched to review the progress and future prospects for clinical development of GMZ2 sub-unit vaccine. We will focus on discovery, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production, pre-clinical and clinical studies. Expert commentary: GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population. More immunogenic formulations should be developed.

Original languageEnglish
JournalExpert Review of Vaccines
Volume16
Issue number9
Pages (from-to)907-917
Number of pages11
ISSN1476-0584
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 52821703